ERBB2 and cancer: Most TNBCs were classified as basal-like by PAM50 (80.6%) through a direct comparison of 374 cancer samples, followed by HER2-enriched (10.2%), normal-like (4.7%), luminal B (3.5%), and luminal A (1.1%); none of the intrinsic subtypes described differed significantly in terms of the rate of pathological complete response (pCR) or survival after chemotherapy [8].